Posts for Ticker ‘ILMN’

Top Day Trader Alerts (AMD, APOL, ETFC, ILMN, LVLT, PVTB)

These are this morning’s top day trader and active trader alerts from us with links through to updates and more detailed price-volume analysis with a link to each stock at VSInvestor.com:

You can join our open email distribution list to get updates on top analyst upgrades and downgrades, top day trader alerts, IPO’s, secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG

Posted on: October 28, 2009 – 9:07 am in Pre-Market Activity, Trading Alert, , , , , ,

Top Analyst Upgrades (DOX, CVX, GS, ILMN, INTU, KBH, HOT, WU)

These are the top pre-market analyst upgrades and positive research calls we have seen from Wall Street early this Thursday morning:

Amdocs (DOX) Raised to Outperform at Oppenheimer.
Chevron (CVX) Started as Buy at Societe Generale.
Goldman Sachs Group (GS) Raised to Buy at BofA/Merrill.
Illumina (ILMN) Raised to Buy at Auriga.
Intuit (INTU) Started as Buy at Deutsche Bank.
KB Home (KBH) Raised to Outperform at Credit Suisse.
Starwood Hotels (HOT) Raised to Market Perform at FBR.
Western Union (WU) Raised to Outperform at Credit Suisse.

JON C. OGG

Posted on: July 9, 2009 – 6:43 am in Analyst Calls, , , , , , , ,

Top Pre-Market Analyst Upgrades (HD, ILMN, MFE, NAV, OMX, VTA, VRNM, WAT)

These are some of the top upgrades or positive calls we are seeing from analysts this Friday morning:

  • Home Depot (HD) Started as Outperform at FBR.
  • Illumina (ILMN) Started as Overweight at Morgan Stanley.
  • McAfee (MFE) Started as Buy at American Technology & Research.
  • Navistar (NAV) Raised to Overweight at JPMorgan.
  • OfficeMax (OMX) Started as Outperform at FBR.
  • Van Kampe Dynamic Credit Fund (VTA) Started as Perform at Oppenheimer.
  • Verenium (VRNM) Started as Buy at Lazard.
  • Waters Corp. (WAT) Started as Overweight at Morgan Stanley.

Jon C. Ogg
September 5, 2008

Posted on: September 5, 2008 – 6:59 am in Analyst Calls, , , , , , , ,

Illumina Gets Secondary Behind It (ILMN)

Illumina Inc. (NASDAQ: ILMN) has priced its proposed secondary offering of 3.5 million shares at $87.50 per share.  This will result in net proceeds of roughly $297.9 million. The sole manager of the offering is Goldman Sachs.

While that is a $1.75 discount from yesterday’s close, it is down from recent highs of $95.75 and around the lows of two-days ago.  Some secondary pricings look bad for holders, but this one doesn’t look too bad with shares down $1.00 from yesterday’s close.

Jon C. Ogg
August 7, 2008

Posted on: August 7, 2008 – 7:17 am in Biotech, Secondary Offering,

Biotech Business Daily (BIIB, GSK, ILMN, IVGN, LJPC, SIRT, STEM)

Biogen Idec (NASDAQ: BIIB) is sliding marginally despite reported earnings today that showed a 23% increase in earnings riding on sales growth on Avonex and Rituxan. The earnings beat estimates and the company raised its outlook. Shares are down $1.06 to $63.56 on a 52-week range of $45.77 to $84.75.

GlaxoSmithKline (NYSE: GSK) is up a marginal 1.5% to $44.42 on a 52-week range of $40.51 to $59.15. Today, the company showed a 13% decline in profit due to increased generic purchases that cut into sales on anti-depressants and heart medications. Yesterday, the company offered to purchase Sirtris Pharmaceuticals for $720 million.

Illumina Inc. (NASDAQ: ILMN) shares are up $8.12, 11%, after solid first quarter earnings that beat estimates and a strong positive outlook. The company posted earnings of $13.4 million after showing a loss of $298 the same quarter last year. Shares are trading at $80.59 and the 52-week range is $31.66 to $79.90.

Invitrogen Corp. (NASDAQ: IVGN) is up 7% after first quarter earnings showed doubled profit on sales increases, beating estimates. The company posted earnings of $58.7 million and $1.19 EPS. Shares are trading at $93.73 on a 52-week range of $65.00 to $99.15.

La Jolla Pharmaceutical Co. (NASDAQ: LJPC) reported positive results on interim antibody data on Riquent for treatment of lupus. Lupus is a condition in which antibodies attack tissues. The results showed that higher dosages of the treatment reduced levels of antibodies more effectively. The late stage trial is expected to close in the second half of 2009. Shares are up 18% to $2.15 on a 52-week range of $1.45 to $7.10.

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) is seeing shares up a whopping 82% after GlaxoSmithKline (NYSE: GSK) offered to buy the company yesterday for $22.50 per share, an 84% premium to Tuesday’s close, for a total value of $720 million. Sirtris focuses on enzymes that affect the aging process and is developing a type-II diabetes treatment. Sirtris shares are up $10.07 to $22.30. The 52-week range is $9.50 to $21.99.

StemCells (NASDAQ: STEM) received a patent for neural stem cells from all tissue sources. This patent will require all other third parties seeking to commercialize neural stems cells to obtain a license from StemCells.  Shares are up $0.18 to $1.55, a 13% jump. The 52-week range is $1.00 to $2.83.

Rachel Lopez
April 23, 2008

Posted on: April 23, 2008 – 11:55 am in Biotech, , , , , , ,

Top 10 Pre-Market Analyst Calls (BSC, CAL, DELL, ESRX, HON, ILMN, NUAN, SPW, STM, AU, DROOY, GFI, GBN, HMY)

These are not the only big analysts calls this Friday morning, but these are the ones that 24/7WallSt.com is focusing on this morning:

  • Bear Stearns (BSC) raised to Buy at Merrill Lynch.
  • Continental (CAL) raised to Outperform from Peer Perform at Bear Stearns.
  • Dell (DELL) raised to Overweight from Neutral at JPMorgan.
  • Express Scripts (ESRX) started as Buy at Deutsche Bank.
  • Honeywell (HON) raised to Neutral at JPMorgan.
  • Illumina (ILMN) raised to Overweight from Equal Weight at Lehman; raised to Buy at UBS.
  • Nuance Communications (NUAN) raised to Buy from Hold at Citigroup.
  • SPX Corp. (SPW) raised to Overweight at JPMorgan.
  • STMicroelectronics (STM) downgraded to Neutral from Outperform.

DEUTSCHE BANK Downgrades Gold Stocks:

  • Anglogold (AU) downgraded to Sell from Hold;
  • DRDGOLD (DROOY) downgraded to Hold from Buy;
  • Gold Fields (GFI) downgraded to Sell from Hold;
  • Great Basin Gold (GBN) downgraded to Hold from Buy;
  • Hamrmony Gold (HMY) downgraded to Sell from Hold.

Jon C. Ogg
January 11, 2008

Posted on: January 11, 2008 – 7:31 am in Analyst Calls, , , , , , , , , , , , , ,

Earlybird Analyst Calls (June 14, 2007)

ACL started as Buy at Jefferies.
AMGN started as Mkt Perform at Rodman & Renshaw.
B started as Outperform at CIBC.
CBB started as Buy at UBS.
CHE started as Buy at Jefferies.
CTL raised to Neutral at UBS.
CYTX started as Mkt Perform at Piper Jaffray.
DJ cut to Reduce at UBS.
EQ raised to Buy at UBS.
ESI cut to Equal Weight at Lehman.
EYE started as Underperform at Jefferies.
GNLB started as Buy at Oppenheimer.
ILMN raised to Outperform at Bear Stearns.
ISIL raised to Buy at B of A.
MFA started as Outperform at JMP Securities.
MNKD started as Buy at B of A.
OPTT started as Outperform at Bear Stearns.
PT raised to Outperform at Credit Suisse.
RACK started as Buy at Merriman Curhan Ford.
RBC started as Sector Perform at CIBC.
SLM cut to Peer Perform at Bear Stearns.
SNY cut to Neutral at HSBC; cut to Neutral at JPMorgan.
THI raised to Outperform at CIBC.
VDSI cut to Hold at Jefferies.
VTIV raised to Strong Buy at First Albany.
WIN started as Neutral at UBS.
ZGEN started as Neutral at Oppenheimer.

Jon C. Ogg
June 14, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 14, 2007 – 6:29 am in Analyst Calls, , , , , , , , , , , , , , , , , , , , , , , , , , ,